Serum levels of adrenal-seminal-pituitary protein in some human neoplasms. by Al-Awqati, M. A. et al.
Br. J. Cancer (1980) 41, 825
Short Communication
SERUM LEVELS OF ADRENAL-SEMINAL-PITUITARY PROTEIN
IN SOME HUMAN NEOPLASMS
M. A. AL-AWQATI*, T. CHARD*, J. C. M. P. MONTEIROt AND A. M. NEVILLEt
From the *Joint Academic Unit of Obstetrics and Gynaecology and Reproductive Physiology,
The Medical College ofSt Bartholomew's Hospital, London EC1, the tBreast Unit,
Royal Marsden Hospital, London SW3 and the +Ludwig Institute for Cancer Research,
Royal Marsden Hospital, Sutton, Surrey
Receivedi 2.t5 October 1979
THE IDENTIFICATION, purification and
development of a radioimmunoassay for a
new and apparently unique adrenal-
seminal-pituitary protein (ASP) has been
described (Al-Awqati et al., 1979a,b).
ASP is a protein with a mol. wt of about
25,000 and an electrophoretic mobility in
the pre-albumin region. The exact bio-
logical function of ASP is unknown,
though recent evidence ofincreased serum
levels after oral administration ofa prosta-
glandin synthetase inhibitor (Froben) indi-
cate that it may be associated with
prostaglandin physiology (Etheridge et al.,
in press).
Serum samples from 74 patients (aged
17-81 years) with leukaemia were assayed
for ASP. Of these patients, 22 had
chronic lymphatic leukaemia (CLL), 15
had acute myeloblastic leukaemia (AML),
15 had acute lymphoblastic leukaemia
(ALL), 13 had acute myelomonocytic
leukaemia (AMML) and 9 had acute mono-
cytic leukaemia (AMOL).
Serum samples were also obtained from
99 patients with localized breast cancer,
101 patients with disseminated breast
cancer and 10 patients with benign breast
tumours. The diagnosis and staging of
disease (including extra-mammary spread)
was based upon conventional clinical,
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histological and radiological criteria.
Serum carcinoembryonic antigen (CEA)
levels were available on 83 of these
samples.
ASP and CEA levels were measured by
radioimmunoassay (Al-Awqati et al.,
1979b; Laurence et al., 1972).
Leukaemia. The results are shown in
Fig. 1. Whilst the mean serum ASP level
of patients with leukaemia was 448 Hg/l
compared to a mean of 240 Htg/l in normal
controls, the most striking elevations
were only seen in AMML and AMOL.
However, 2 cases of CLL had ASP levels
higher than any of the values seen in
AMOL.
Breast cancer. The results are shown
in Figs 2 and 3. In all patients with benign
breast lumps, serum ASP levels were
within the normal range (80-450 fkg/l). In
contrast, high concentrations of ASP
(above the 95th centile of controls) were
detected in 23% and 25% ofpatients with
apparently localized and disseminated
breast cancer respectively. No true dis-
tinction between localized and metastatic
breast cancer was seen on the basis of
ASP though this could be obtained with
CEA (Fig. 3). There was no correlation
between ASP and CEA levels. Only
patients with disseminated disease ex-
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FIG. 1.-Serum ASP levels in normal human sera (NHS) an(l in patients with leukaemia, clhronic
lymphatic (CLL), acute myeloblastic (AML), acute lymphoblastic (ALL), acute myelomonocytic
(AMML) an(d acute monocytic (AML). The 95th centile (-- - -) of normal controls is also shown.
hibited a concordant elevation of both
proteins.
ASP is a newly described human pro-
tein occurring at very high concentrations
in the adrenal and pituitary glands. The
fact that high levels of this protein are
also found in seminal plasma, together
with the observed changes in serum ASP
levels after oral ingestion of a prosta-
glandin synthetase inhibitor (Etheridge
et al., in press) suggest that ASP is closely
related to some aspect of prostaglandin
physiology. For the past few years, prosta-
glandins have been increasingly implicated
in many aspects of tumour development
and growth (Editorial Lancet, 1979;
Jaffe, 1974). However, there is no evidence
of an association between prostaglandins
and breast cancer or leukaemias. The
results of this study are of great interest
in view of both the general elevation in
serum ASP levels and, more important,
the striking differencesbetweenthevarious
types ofleukaemia studied. At the present
time, and until more is known about the
exact biology of ASP, it is futile to specu-
late on the relationship between this pro-
tein and the neoplastic process; e.g.
whether it is a primary product of the
tumour cells, or the result of a secondary
response to the tumour. Nevertheless,
these preliminary observations should
prompt further investigations into
the pathological significance of raised
serum levels of ASP in human neo-
plasms.
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FIG. 2.-Serum ASP levels in pre-operative samples from patients with benign and malignant breast disease.
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FIG. 3.-Correlation between ASP and CEA in patients with localized (0) and disseminated (0) breast
cancer. Malignancy is strongly suspected with serum CEA levels equal to or above 30 tg/l.
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